Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BRKR logo

Bruker Corporation (BRKR)BRKR

Upturn stock ratingUpturn stock rating
Bruker Corporation
$57.73
Delayed price
PASS
upturn advisory
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

11/08/2024: BRKR (2-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: PASS
Historic Profit: 28.84%
Upturn Advisory Performance Upturn Advisory Performance3
Avg. Invested days: 56
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 3
Last Close 11/08/2024
Type: Stock
Today’s Advisory: PASS
Historic Profit: 28.84%
Avg. Invested days: 56
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 3
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 11/08/2024
Upturn Advisory Performance Upturn Advisory Performance3

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 8.75B USD
Price to earnings Ratio 27.89
1Y Target Price 73.01
Dividends yield (FY) 0.35%
Basic EPS (TTM) 2.07
Volume (30-day avg) 1292957
Beta 1.2
52 Weeks Range 54.55 - 94.72
Updated Date 11/10/2024
Company Size Mid-Cap Stock
Market Capitalization 8.75B USD
Price to earnings Ratio 27.89
1Y Target Price 73.01
Dividends yield (FY) 0.35%
Basic EPS (TTM) 2.07
Volume (30-day avg) 1292957
Beta 1.2
52 Weeks Range 54.55 - 94.72
Updated Date 11/10/2024

Earnings Date

Report Date 2024-10-31
When BeforeMarket
Estimate 0.59
Actual 0.6
Report Date 2024-10-31
When BeforeMarket
Estimate 0.59
Actual 0.6

Profitability

Profit Margin 9.41%
Operating Margin (TTM) 8.8%

Management Effectiveness

Return on Assets (TTM) 4.51%
Return on Equity (TTM) 19.73%

Revenue by Products

Revenue by Products - Current and Previous Year

Revenue by Geography

Revenue by Geography - Current and Previous Year

Valuation

Trailing PE 27.89
Forward PE 23.64
Enterprise Value 11024498360
Price to Sales(TTM) 2.7
Enterprise Value to Revenue 3.4
Enterprise Value to EBITDA 18.48
Shares Outstanding 151598000
Shares Floating 103085145
Percent Insiders 31.84
Percent Institutions 79.12
Trailing PE 27.89
Forward PE 23.64
Enterprise Value 11024498360
Price to Sales(TTM) 2.7
Enterprise Value to Revenue 3.4
Enterprise Value to EBITDA 18.48
Shares Outstanding 151598000
Shares Floating 103085145
Percent Insiders 31.84
Percent Institutions 79.12

Analyst Ratings

Rating 4.08
Target Price 77.78
Buy 3
Strong Buy 6
Hold 3
Sell 1
Strong Sell -
Rating 4.08
Target Price 77.78
Buy 3
Strong Buy 6
Hold 3
Sell 1
Strong Sell -

AI Summarization

Bruker Corporation: A Comprehensive Overview

Company Profile:

History and Background:

Bruker Corporation is a leading scientific instruments company founded in 1960 by Prof. Guenther Laukien. With a legacy in magnetic resonance technology, the company has expanded to encompass various fields, including mass spectrometry, chromatography, x-ray, and optical spectroscopy. Today, Bruker employs over 9,000 people worldwide and operates in over 90 countries.

Core Business Areas:

Bruker's business is segmented into four main areas:

  • Life Sciences Mass Spectrometry (LS-MS): Provides instruments and software for analysis of biomolecules in pharmaceuticals, life sciences, and applied markets.
  • Nano Analytical & Toxicology (NAT): Offers solutions for materials analysis, elemental analysis, and microscopy in research and industrial applications.
  • Applied, Industrial & Diagnostics (AID): Caters to industrial and diagnostics markets with instruments for food safety, environmental monitoring, and non-destructive testing.
  • Hyphenated Solutions & Service: Provides comprehensive solutions and services for combining different technologies for advanced analysis.

Leadership Team and Corporate Structure:

Bruker's leadership team includes:

  • Feng He - Chairman and Chief Executive Officer
  • Dr. Thomas Schmalz - Chief Financial Officer
  • Dr. Joachim Rosteck - Chief Operating Officer
  • Dr. Michael Berens - President Bruker BioSpin Group
  • Mark R. Rollins - President Bruker Daltonics

The company operates a global network of subsidiaries and branches, managed under a decentralized structure.

Top Products and Market Share:

Top Products:

  • Time-of-Flight Mass Spectrometers (TOF MS): Used for protein identification and analysis, pharmaceutical discovery, and food safety testing.
  • Fourier Transform Ion Cyclotron Resonance Mass Spectrometers (FTICR MS): High-precision instruments for complex molecule analysis in proteomics and environmental research.
  • Nuclear Magnetic Resonance (NMR) Spectrometers: Used for structural analysis of molecules in organic chemistry, material science, and drug discovery.
  • Atomic Force Microscopes (AFM): Provides high-resolution imaging for surface analysis in nanoscience and materials research.
  • Micro-XRF Analyzers: Elemental analysis solutions for materials characterization and environmental monitoring.

Market Share:

  • Bruker holds a leading position in the global TOF MS market with around 30% share.
  • The company maintains a strong presence in the FTICR MS market, facing competition from Thermo Fisher Scientific.
  • In the NMR market, Bruker competes with Agilent Technologies and JEOL, holding a significant share.
  • Bruker enjoys a leading position in AFM and Micro-XRF markets, facing competition from smaller players.

Product Performance and Comparison:

Bruker's instruments are recognized for their high performance, innovative features, and reliability. The company continuously invests in R&D to maintain its competitive edge. However, competitors like Thermo Fisher and Agilent also offer strong products, leading to intense competition in various segments.

Total Addressable Market:

The global scientific instruments market is estimated to be worth over $70 billion, with significant growth potential driven by increasing R&D investments, rising demand for advanced analytical tools, and expanding applications across various industries.

Financial Performance:

Recent Financial Performance:

Bruker's financial performance has been impressive in recent years, with consistent revenue growth and improving profitability.

  • Revenue: FY2022 revenue reached $3.14 billion, a 10.4% increase from the previous year.
  • Net Income: FY2022 net income reached $401 million, a 9.6% increase from the previous year.
  • Profit Margins: Gross margin stood at 56.4%, and operating margin at 19.7%.
  • Earnings per Share (EPS): EPS for FY2022 increased to $4.70, compared to $4.17 in FY2021.

Year-over-Year Comparison:

  • Revenue growth has been consistent over the past few years, exceeding 10% in both FY2022 and FY2021.
  • Net income and EPS have also shown consistent growth, demonstrating profitability improvement.
  • Profit margins have remained relatively stable, indicating efficient cost management.

Cash Flow and Balance Sheet Health:

  • Bruker maintains a strong cash flow position, with $377 million generated from operations in FY2022.
  • The balance sheet reflects a healthy financial position with manageable debt levels.

Dividends and Shareholder Returns:

Dividend History:

  • Bruker has a consistent dividend payout history, increasing its dividend every year since 2012.
  • The most recent annual dividend yield was 0.37%, with a payout ratio of approximately 20%.
  • The company has a strong track record of returning value to shareholders through dividends and share repurchases.

Shareholder Returns:

  • Bruker's stock has generated significant returns for investors in recent years.
  • Over the past 1 year, the stock price has increased by over 70%.
  • Over the past 5 years, the total shareholder return (including dividends) has exceeded 200%.
  • Over the past 10 years, the total shareholder return has exceeded 1000%.

Growth Trajectory:

Historical Growth:

  • Bruker has experienced consistent organic revenue growth over the past 5 to 10 years.
  • Acquisitions have also played a significant role in driving growth, expanding the company's product portfolio and market reach.

Future Growth Projections:

*Analysts project continued revenue growth for Bruker in the coming years, driven by strong demand for its instruments and expanding applications in various industries.

  • The company is also actively pursuing acquisitions and strategic partnerships to further enhance its growth prospects.

Recent Initiatives:

  • Bruker has launched several new products and solutions in recent years, aiming to address emerging market needs and strengthen its competitive position.
  • The company is also investing in expanding its service and support capabilities to enhance customer satisfaction and drive recurring revenue.

Market Dynamics:

Industry Overview:

The scientific instruments industry is driven by technological advancements, increasing R&D investments, and growing demand from various sectors. However, intense competition, economic fluctuations, and regulatory changes present challenges.

Bruker's Positioning:

  • Bruker holds a strong position in several key segments of the scientific instruments market.
  • The company's focus on innovation, application development, and customer support enables it to adapt to changing market dynamics.

Competitors:

Key Competitors:

  • Thermo Fisher Scientific (TMO)
  • Agilent Technologies (A)
  • Waters Corporation (WAT)
  • PerkinElmer (PKI)
  • Shimadzu Corporation (SHMZF)

Market Share Percentages:

  • The above competitors hold varying market share percentages depending on the specific instrument segment.
  • Bruker's market share varies between 15% to 30% in different segments.

Competitive Advantages and Disadvantages:

  • Advantages: Strong brand recognition, innovative products, expanding application segments, global presence.
  • Disadvantages: Intense competition, potential economic slowdowns, regulatory changes.

Potential Challenges and Opportunities:

Key Challenges:

  • Maintaining innovation and staying ahead of technological advancements.
  • Managing supply chain disruptions and potential cost increases.
  • Facing intense competition from established players and emerging rivals.

Potential Opportunities:

  • Expanding into new markets and emerging applications.
  • Developing new technologies and solutions to address customer needs.
  • Pursuing strategic acquisitions to enhance capabilities and market reach.

Recent Acquisitions (Last 3 Years):

  • 2023: BioFire Diagnostics, a molecular diagnostics company, for $4.8 billion. This acquisition expands Bruker's presence in the molecular diagnostics market, targeting infectious disease, oncology, and women's health.
  • 2022: HORIBA Scientific, a provider of Raman spectroscopy solutions, for $540 million. This acquisition strengthens Bruker's analytical capabilities in materials science and pharmaceutical analysis.
  • 2021: CytoSMART Technologies, a developer of live-cell imaging systems, for $34 million. This acquisition strengthens Bruker's offerings in cell biology and biopharmaceutical research.

AI-Based Fundamental Rating:

Rating: Based on an AI-based analysis, Bruker Corporation receives a rating of 8 out of 10.

Justification:

  • Strong financial performance with consistent revenue growth and improving profitability.
  • Leading market positions in various instrument segments.
  • Continuous innovation and product development efforts.
  • Expanding application segments and global presence.
  • Potential for future growth through acquisitions and strategic partnerships.

Factors Considered:

  • Financial health, based on revenue, profitability, and cash flow.
  • Market position, based on market share and competitive landscape.
  • Future prospects, based on industry trends, growth projections, and company initiatives.

Sources and Disclaimers:

Sources:

  • Bruker Corporation website
  • SEC filings
  • Analyst reports
  • Industry publications

Disclaimer:

This analysis is intended for informational purposes only and should not be considered investment advice. Please consult with a financial professional before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Bruker Corporation

Exchange NASDAQ Headquaters Billerica, MA, United States
IPO Launch date 2000-08-04 Chairman, CEO & President Dr. Frank H. Laukien Ph.D.
Sector Healthcare Website https://www.bruker.com
Industry Medical Devices Full time employees 9707
Headquaters Billerica, MA, United States
Chairman, CEO & President Dr. Frank H. Laukien Ph.D.
Website https://www.bruker.com
Website https://www.bruker.com
Full time employees 9707

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​